| 1. |
- Bendsoe, N., et al.
(författare)
-
A Non-Interventional Study on Vismodegib for Basal Cell Carcinoma in Swedish Patients
- 2023
-
Ingår i: Dermatology Practical & Conceptual. - : Mattioli1885. - 2160-9381. ; 13:2
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Real-life data on vismodegib in advanced basal cell carcinoma (aBCC) are limited. Optimal treatment duration is left to the discretion of the physician.Objectives: To assess the effectiveness, safety and treatment pattern for vismodegib in aBCC in clinical practice.Methods: In this multicenter, non-interventional, prospective study, 49 Swedish patients planned for vismodegib treatment were included. The treatment pattern observed was treatment until remission, allowing unlimited discontinuations/pauses.Results: The majority of patients (93.8%), discontinued at least once during the study. Compared to earlier studies there was a decrease of more than 2 months with actual drug intake, reducing the patients burden and costs, at the same time as a high number of responses were seen (87.8%). Median progression-free-survival was 16.7 months, and 90% of the patients were alive at 13.3 months. Ten patients were re-challenged with vismodegib at recurrence or progression, resulting in five partial remissions and three complete remissions.Conclusions: Clinical response rates with vismodegib for aBCC were comparable to those of similar trials despite a shorter and more intermittent treatment duration. The majority of re-challenges lead to partial or complete remissions.
|
|
| 2. |
|
|
| 3. |
- Svensson, Jenny, et al.
(författare)
-
Tumor selectivity at short times following systemic administration of a liposomal temoporfin formulation in a murine tumor model
- 2007
-
Ingår i: Photochemistry and Photobiology. - 0031-8655. ; 83:5, s. 1211-1219
-
Tidskriftsartikel (refereegranskat)abstract
- Meso-tetra(hydroxyphenyl)chlorin (mTHPC) (INN: Temoporfin) is one of the most potent photodynamically active substances in clinical use. Treatment protocols for Temoporfin-mediated photodynamic therapy often rely on drug-light intervals of several days in order for the photosensitizer to accumulate within the target tissue, though tumor selectivity is limited. Here, the mTHPC localization was studied at 2-8 h following systemic administration of a liposomal Temoporfin formulation (0.15 mg kg(-1) b.w.) in HT29 human colon adermcarcinoma in NMRI nu/nu mice. Photosensitizer distribution within tumor and internal organs was investigated by means of high performance liquid chromatography following chemical extraction, as well as in situ fluorescence imaging and point-monitoring fluorescence spectroscopy. For tumor tissue, the Temoporfin concentrations at 4 h (0.16 +/- 0.024 ng mg(-1)) and 8 h (0.18 +/- 0.064 ng mg(-1)) were significantly higher than at 2 It (0.08 +/- 0.026 ng mg(-1)). The average tumor-to-muscle and the tumor-to-skin selectivity were 6.6 and 2, respectively, and did not vary significantly with time after photosensitizer injection. In plasma, the Temoporfin concentration was low (0.07 +/- 0.07 ng mg(-1)) and showed no significant variation with time. Our results indicate a rapid biodistribution and clearance from the bloodstream. Within the same type of organ, data from both fluorescence methods generally exhibited a significant correlation with the extraction results.
|
|
